Haemonetics Corporation (HAE) Stake Decreased by Chartwell Investment Partners LLC, Report finds

Haemonetics Corporation (HAE) Stake Decreased by Chartwell Investment Partners LLC, Report finds

Chartwell Investment Partners LLC cut its stake in Haemonetics Corporation (NYSE:HAE) by 8.9% during the third quarter, Holdings Channel reports. The firm owned 369,513 shares of the company’s stock after selling 36,100 shares during the period. Chartwell Investment Partners LLC owned about 0.72% of Haemonetics Corporation worth $13,380,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HAE. Louisiana State Employees Retirement System boosted its stake in shares of Haemonetics Corporation by 0.4% in the second quarter. Louisiana State Employees Retirement System now owns 22,600 shares of the company’s stock valued at $655,000 after buying an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of Haemonetics Corporation by 1.7% in the third quarter. Municipal Employees Retirement System of Michigan now owns 11,330 shares of the company’s stock valued at $410,000 after buying an additional 190 shares during the last quarter. AMG National Trust Bank boosted its stake in shares of Haemonetics Corporation by 1.3% in the third quarter. AMG National Trust Bank now owns 15,755 shares of the company’s stock valued at $570,000 after buying an additional 197 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Haemonetics Corporation by 0.6% in the second quarter. JPMorgan Chase & Co. now owns 34,619 shares of the company’s stock valued at $1,003,000 after buying an additional 201 shares during the last quarter. Finally, Confluence Investment Management LLC boosted its stake in shares of Haemonetics Corporation by 0.4% in the third quarter. Confluence Investment Management LLC now owns 56,190 shares of the company’s stock valued at $2,035,000 after buying an additional 230 shares during the last quarter. Institutional investors and hedge funds own 99.43% of the company’s stock.

Shares of Haemonetics Corporation (NYSE:HAE) traded down 0.67% during trading on Wednesday, reaching $36.90. The company had a trading volume of 546,617 shares. Haemonetics Corporation has a 12-month low of $25.98 and a 12-month high of $41.65. The firm has a 50-day moving average of $39.78 and a 200-day moving average of $37.35. The company’s market cap is $1.91 billion.

Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Monday, February 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. Haemonetics Corporation had a net margin of 1.79% and a return on equity of 10.51%. The company earned $227.80 million during the quarter, compared to analysts’ expectations of $220 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. Haemonetics Corporation’s quarterly revenue was down 2.4% compared to the same quarter last year. On average, equities research analysts anticipate that Haemonetics Corporation will post $1.52 EPS for the current year.

Several analysts have issued reports on HAE shares. BTIG Research restated a “neutral” rating on shares of Haemonetics Corporation in a research note on Monday, November 7th. Benchmark Co. upped their price objective on Haemonetics Corporation from $32.00 to $34.00 and gave the company a “hold” rating in a research note on Monday, November 7th. Zacks Investment Research cut Haemonetics Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, January 5th. Barrington Research cut Haemonetics Corporation from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Finally, Off Wall Street began coverage on Haemonetics Corporation in a research note on Friday, October 14th. They set a “sell” rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. Haemonetics Corporation has an average rating of “Hold” and a consensus target price of $34.57.

In other news, Director Ronald G. Gelbman sold 5,683 shares of Haemonetics Corporation stock in a transaction that occurred on Monday, December 12th. The shares were sold at an average price of $40.30, for a total value of $229,024.90. Following the completion of the transaction, the director now owns 49,688 shares in the company, valued at $2,002,426.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Related posts

Leave a Comment

Haemonetics Corporation (HAE) Stake Decreased by Chartwell Investment Partners LLC

Haemonetics Corporation (HAE) Stake Decreased by Chartwell Investment Partners LLC

Chartwell Investment Partners LLC cut its stake in Haemonetics Corporation (NYSE:HAE) by 8.9% during the third quarter, Holdings Channel reports. The firm owned 369,513 shares of the company’s stock after selling 36,100 shares during the period. Chartwell Investment Partners LLC owned about 0.72% of Haemonetics Corporation worth $13,380,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HAE. Louisiana State Employees Retirement System boosted its stake in shares of Haemonetics Corporation by 0.4% in the second quarter. Louisiana State Employees Retirement System now owns 22,600 shares of the company’s stock valued at $655,000 after buying an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of Haemonetics Corporation by 1.7% in the third quarter. Municipal Employees Retirement System of Michigan now owns 11,330 shares of the company’s stock valued at $410,000 after buying an additional 190 shares during the last quarter. AMG National Trust Bank boosted its stake in shares of Haemonetics Corporation by 1.3% in the third quarter. AMG National Trust Bank now owns 15,755 shares of the company’s stock valued at $570,000 after buying an additional 197 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Haemonetics Corporation by 0.6% in the second quarter. JPMorgan Chase & Co. now owns 34,619 shares of the company’s stock valued at $1,003,000 after buying an additional 201 shares during the last quarter. Finally, Confluence Investment Management LLC boosted its stake in shares of Haemonetics Corporation by 0.4% in the third quarter. Confluence Investment Management LLC now owns 56,190 shares of the company’s stock valued at $2,035,000 after buying an additional 230 shares during the last quarter. Institutional investors and hedge funds own 99.43% of the company’s stock.

Shares of Haemonetics Corporation (NYSE:HAE) traded down 0.67% during trading on Wednesday, reaching $36.90. The company had a trading volume of 546,617 shares. Haemonetics Corporation has a 12-month low of $25.98 and a 12-month high of $41.65. The firm has a 50-day moving average of $39.78 and a 200-day moving average of $37.35. The company’s market cap is $1.91 billion.

Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Monday, February 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. Haemonetics Corporation had a net margin of 1.79% and a return on equity of 10.51%. The company earned $227.80 million during the quarter, compared to analysts’ expectations of $220 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. Haemonetics Corporation’s quarterly revenue was down 2.4% compared to the same quarter last year. On average, equities research analysts anticipate that Haemonetics Corporation will post $1.52 EPS for the current year.

Several analysts have issued reports on HAE shares. BTIG Research restated a “neutral” rating on shares of Haemonetics Corporation in a research note on Monday, November 7th. Benchmark Co. upped their price objective on Haemonetics Corporation from $32.00 to $34.00 and gave the company a “hold” rating in a research note on Monday, November 7th. Zacks Investment Research cut Haemonetics Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, January 5th. Barrington Research cut Haemonetics Corporation from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Finally, Off Wall Street began coverage on Haemonetics Corporation in a research note on Friday, October 14th. They set a “sell” rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. Haemonetics Corporation has an average rating of “Hold” and a consensus target price of $34.57.

In other news, Director Ronald G. Gelbman sold 5,683 shares of Haemonetics Corporation stock in a transaction that occurred on Monday, December 12th. The shares were sold at an average price of $40.30, for a total value of $229,024.90. Following the completion of the transaction, the director now owns 49,688 shares in the company, valued at $2,002,426.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Related posts

Leave a Comment